IntegraGen

IntegraGen SA uses its unique genomic analysis expertise to identify genes associated with complex diseases and to develop diagnostic and predictive genetic tests. The Company applies its innovative gene mapping technology, GenomeHIP® (Genome Hybrid Identity Profiling), to rapidly discover genetic loci that are implicated in complex, multi-factorial diseases. GenomeHIP® is a major advance that overcomes the limitations of existing marker based familial linkage study methods.

IntegraGen is applying its discoveries to develop a series of innovative IntegraTests™ and is poised to become a leader in the rapidly growing field of predictive medicine. The Company will be a fully integrated provider of genetic tests that can be used to predict, prevent, diagnose and tailor personalized treatments for complex diseases. Testing will be provided as a service through Expert Centers, which will also provide expert analysis and genetic counseling from an accredited MD-geneticist. The Company’s first Expert Center was established earlier this year in Bonn, Germany, to provide the Company’s first testing service for MODY diabetes (Mature Onset Diabetes of the Young). The Company’s strategy is to develop molecular diagnostic tools for selected disease areas with high medical need. IntegraGen’s in-house programs are focused on neurological disorders, including autism and bi-polar disorder, and metabolic disorders, such as obesity and type 2 diabetes mellitus.

Founded in July 2000, IntegraGen has 34 employees and is based in the French Genopole of Evry, near Paris, France, and in Bonn, Germany.